Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Rhythm Pharmaceuticals, Inc. (RYTM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
11.10-0.08 (-0.72%)
At close: 4:00PM EDT
11.10 0.00 (0.00%)
After hours: 04:00PM EDT
Advertisement

Rhythm Pharmaceuticals, Inc.

222 Berkeley Street
12th Floor
Boston, MA 02116
United States
857 264 4280
http://www.rhythmtx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees90

Key Executives

NameTitlePayExercisedYear Born
Dr. David P. Meeker M.D.Chairman, Pres & CEO836.08kN/A1954
Mr. Hunter C. SmithCFO & Treasurer692.84kN/A1969
Ms. Jennifer L. ChienExec. VP & Head of North America194.95kN/A1975
Mr. William T. RobertsChief Accounting OfficerN/AN/A1979
Mr. Joseph ShulmanSr. VP of Technical OperationsN/AN/AN/A
Mr. David ConnollyHead of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Jim FlahertySr. VP & Gen. CounselN/AN/AN/A
Mr. Satej BhandarkarSr. VP of Program Management, Strategy & Corp. Devel.N/AN/AN/A
Ms. Pamela CramerChief HR OfficerN/AN/AN/A
Mr. Yann MazabraudExec. VP & Head of InternationalN/AN/A1973
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Corporate Governance

Rhythm Pharmaceuticals, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 9. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement